Cellino Biotech

Cellino Biotech is a regenerative medicine company manufacturing stem cell-derived medicines by leveraging AI, machine learning, gene editing, and laser technologies to automate the manufacturing of cell therapies—allogeneic therapies (which use donor cells) and autologous therapies (which use the patient’s own cells). 

Cellino intended to solve the time-consuming manual work and high overhead costs required for stem cell-derived therapies by developing a system to manufacture induced pluripotent stem (iPS) cells. It uses a cell-editing laser system and machine learning to automate the process of eliminating sub-par cells that cannot be used for regenerative medicine (which is generally a labor-intensive process) and to process thousands of patient samples required for large-scale manufacturing of iPS cells. By 2025, it aims to build an autonomous human cell foundry.

Key customers and partnerships

Cellino Biotech has a long-term collaboration with the National Institutes of Health (NIH), which is initiating the first autologous iPS cells-derived clinical trial in the US. 

Funding and financials

In January 2022 , Cellino Biotech raised USD 80 million in a Series A funding fund co-led by Leaps by Bayer and Humboldt Fund. Among others, existing investor Khosla Ventures and new investor Felicis Ventures also participated in the round. The funds were expected to advance its platform and hardware capabilities. It also planned to build a Good Manufacturing Practices (GMP) standard facility for clinical trials.